title: Incidence, diagnosis, and therapy of cholangiocarcinoma in patients with primary sclerosing cholangitis.
abstract: Primary sclerosing cholangitis (PSC) can lead to the development of cholangiocarcinoma (CCA). The tumor may present as an intrahepatic focal cholangiocellular carcinoma but more often as a ductal infiltrating desmoplastic lesion. CCA is found synchronously with the diagnosis of PSC in 20-30% and within 1 year in 50%. During later follow-up, the yearly developmental rate of CCA is 0.5-1.5%. Most patients with PSC and CCA do not yet have cirrhosis but present with a severe stenosis at the hilum of the liver. This type of tumor is difficult to diagnose by imaging techniques.(18)F-FDG-PET scanning and CEA or CA 19-9 are not early diagnostic tools. Regular MRI, multislice CT, and repeated endoscopically obtained brush cytology of stenotic lesions are recommended. The recent use of more extensive surgical resection techniques in patients with CCA results in 5-year survival rates of > or =50%. If tumors are small or incidental findings, liver transplantation leads to a 3- to 5-year survival rate of 35%. Pretransplant radiotherapy with 5-FU chemosensitization followed by endoscopic brachytherapy with iridium-192 seems to greatly improve the outcome of transplantation. Treatment with ursodeoxycholic acid may prevent development of CCA.
authors: Division of Hepatobiliary, University Hospital Gasthuisberg, Catholic University of Leuven, B3000 Leuven, Belgium. Johan.Fevery@med.kuleuven.be
authors: Johan
authors: J
authors: Fevery
authors: Chris
authors: C
authors: Verslype
authors: Gillian
authors: G
authors: Lai
authors: Raymond
authors: R
authors: Aerts
authors: Werner
authors: W
authors: Van Steenbergen
mesh_terms: D000293:Adolescent; D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D001530:Belgium / Q000453:epidemiology; D001650:Bile Duct Neoplasms / Q000175:diagnosis / Q000453:epidemiology* / Q000209:etiology / Q000628:therapy; D001653:Bile Ducts, Intrahepatic; D001706:Biopsy; D001918:Brachytherapy / Q000379:methods; D018281:Cholangiocarcinoma / Q000175:diagnosis / Q000453:epidemiology* / Q000209:etiology / Q000628:therapy; D002760:Cholangiopancreatography, Endoscopic Retrograde; D015209:Cholangitis, Sclerosing / Q000150:complications*; D003937:Diagnosis, Differential; D018450:Disease Progression; D019160:Endosonography; D017809:Fatal Outcome; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D015994:Incidence; D008279:Magnetic Resonance Imaging; D008297:Male; D049268:Positron-Emission Tomography; D012189:Retrospective Studies; D014057:Tomography, X-Ray Computed